Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022

Rhea-AI Summary

Rain Therapeutics Inc. (NASDAQ: RAIN) will present a poster and two trials at the AACR Annual Meeting 2022 from April 8-13. The poster, titled Exploration of MDM2 gene amplification, emphasizes the prognosis in solid tumors and will be presented by Dr. Vijaya Tirunagaru on April 11. The ongoing trials include a phase 2 study of the MDM2 inhibitor milademetan and a phase 3 trial comparing it against trabectedin in liposarcomas. These presentations highlight Rain's focus on precision oncology and genetic patient selection for better therapeutic outcomes.

Positive

• Presentation of significant research at AACR Annual Meeting
• Ongoing phase 2 and phase 3 trials for milademetan highlight drug development progress
• Focus on precision oncology aligns with current industry trends

Negative

• None.

NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.

Poster Presentation Title:	Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors
Abstract Number:	1174 / 4
Presenter:	Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA
Poster Session Date and Time:	Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT
Location:	Poster Section 27
Trial in Progress Title:	A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
Abstract Number:	CT123/5
Presenter:	Ecaterina I. Dumbrava, M.D., Medical Oncologist, The University of Texas MD Anderson Cancer Center
Session Date and Time	Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT
Location:	Poster Section 34
Trial in Progress Title:	MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
Abstract Number:	CT235/6
Presenter:	Mrinal M. Gounder, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center
Session Date and Time:	Tuesday, April 12, 2022, 1:30 p.m. – 5:00 p.m. CT
Location:	Poster Section 36

A copy of the presentation materials can be accessed by visiting the "Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

What is Rain Therapeutics' focus for their presentations at the AACR Annual Meeting 2022?

Rain Therapeutics is focusing on precision oncology, presenting research on MDM2 gene amplification and ongoing clinical trials for their drug milademetan.

When will Rain Therapeutics present their poster at the AACR Annual Meeting 2022?

The poster presentation will take place on April 11, 2022, from 9:00 a.m. to 12:30 p.m. CT.

What are the titles of the trials being presented by Rain Therapeutics?

The trials are titled 'A phase 2 study of the MDM2 inhibitor milademetan' and 'MANTRA: A randomized phase 3 study of milademetan versus trabectedin'.

Where can I find additional resources post-presentation from Rain Therapeutics?

Additional resources will be available on Rain's website in the 'Resources' section after the conclusion of the presentations.

What is milademetan and its relevance in Rain Therapeutics' research?

Milademetan is a small molecule, oral inhibitor of MDM2, significant for targeting oncogenic drivers in various cancers.